Malignant tumours is one of the top causes of death globally. In recent years, one person is diagnosed with a tumour every 6 minutes. The latest technology can detect and identify tumours from a blood sample. CBT’s preTes tumour screening system represents one of the world’s highly comprehensive and accurate gold standard tumour detection technology—circulating tumour DNA (ctDNA) technology, overcoming the challenge of detecting tumours in its precancerous state.
preTes Ultra Early Tumour Screening can provide an early diagnosis from 3 to 5 years in advance from its cancerous stage.
preTes covers nasopharyngeal carcinoma, chloangiocarcinoma, small cell lung cancer, liver cancer, osteosarcoma, melanoma, laryngeal cancer, acute myeloid leukemia, thyroid cancer, colorectal cancer, non-small cell lung cancer (NCLC), esophagus squamous cell carcinoma, bladder cancer, soft tissue tumour, kidney cancer, adrenal adenoma, esophageal adenocarcinoma, gastric cancer, pancreatic cancer, mediastinal tumour, Hodgkin's lymphoma, non-Hodgkin's lymphoma, gastrointestinal stromal tumour, urethral cancer, gallbladder cancer, myelodysplastic syndrome, prostate cancer, head and neck cancer, cervical cancer, ovarian cancer, breast cancer and endometrial cancer.